CN110650963B - Gdc-0077的多晶型物和固体形式及其制备方法 - Google Patents

Gdc-0077的多晶型物和固体形式及其制备方法 Download PDF

Info

Publication number
CN110650963B
CN110650963B CN201880028227.3A CN201880028227A CN110650963B CN 110650963 B CN110650963 B CN 110650963B CN 201880028227 A CN201880028227 A CN 201880028227A CN 110650963 B CN110650963 B CN 110650963B
Authority
CN
China
Prior art keywords
crystalline
polymorph
gdc
cancer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880028227.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110650963A (zh
Inventor
P·查克拉瓦蒂
韩翀
S·M·凯利
K·纳格普迪
S·萨维奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62492573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110650963(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN110650963A publication Critical patent/CN110650963A/zh
Application granted granted Critical
Publication of CN110650963B publication Critical patent/CN110650963B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CN201880028227.3A 2017-04-28 2018-04-26 Gdc-0077的多晶型物和固体形式及其制备方法 Active CN110650963B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491812P 2017-04-28 2017-04-28
US62/491,812 2017-04-28
PCT/EP2018/060820 WO2018197653A1 (en) 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Publications (2)

Publication Number Publication Date
CN110650963A CN110650963A (zh) 2020-01-03
CN110650963B true CN110650963B (zh) 2022-09-27

Family

ID=62492573

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880028227.3A Active CN110650963B (zh) 2017-04-28 2018-04-26 Gdc-0077的多晶型物和固体形式及其制备方法

Country Status (13)

Country Link
US (4) US20180339997A1 (enExample)
EP (2) EP3615541B1 (enExample)
JP (2) JP6998969B2 (enExample)
KR (1) KR102342776B1 (enExample)
CN (1) CN110650963B (enExample)
AU (1) AU2018259089B2 (enExample)
CA (1) CA3048591A1 (enExample)
ES (1) ES3027566T3 (enExample)
IL (3) IL298518B2 (enExample)
MX (1) MX394540B (enExample)
PL (1) PL3615541T3 (enExample)
TW (1) TWI826373B (enExample)
WO (1) WO2018197653A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
IL298518B2 (en) * 2017-04-28 2025-05-01 Hoffmann La Roche Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation
JP7365073B2 (ja) * 2019-05-21 2023-10-19 ジァンスー フォアフロント ファーマシューティカル カンパニー，リミテッド トレプロスチニルナトリウムの新規な結晶形および製造方法
CA3144791A1 (en) * 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
CN113227101B (zh) * 2019-11-25 2024-10-11 上海翰森生物医药科技有限公司 含三并环类衍生物的盐或晶型及其药物组合物
TWI801730B (zh) * 2020-04-07 2023-05-11 神雲科技股份有限公司 具系統設定資料同步功能的伺服器
WO2022161347A1 (zh) * 2021-01-29 2022-08-04 南京明德新药研发有限公司 三并环类化合物及其应用
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762576A (zh) * 2009-09-28 2012-10-31 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法
WO2017001645A1 (en) * 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN110088111A (zh) * 2016-12-15 2019-08-02 豪夫迈·罗氏有限公司 (S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂卓-9-基)氨基)丙酰胺的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
US9266903B2 (en) 2013-12-16 2016-02-23 Genentech, Inc. Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
IL298518B2 (en) 2017-04-28 2025-05-01 Hoffmann La Roche Polymorphs and solid forms of (S)–2–((2–((S–4–(difluoromethyl)–2–oxoxazolidin-3–yl)–5,6–dihydrobenzo[F]imidazo[1,2–D][1,4]oxazepin-9–yl)amino)propanamide and methods of preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762576A (zh) * 2009-09-28 2012-10-31 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法
WO2017001645A1 (en) * 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
CN110088111A (zh) * 2016-12-15 2019-08-02 豪夫迈·罗氏有限公司 (S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂卓-9-基)氨基)丙酰胺的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Crystalline Polymorphism of Organic Compounds;CAIRA ED-MONTCHAMP JEAN-LUC;《TOPICS IN CURRENT CHEMISTRY》;19980101;第198卷;第163-208页 *

Also Published As

Publication number Publication date
WO2018197653A1 (en) 2018-11-01
US20200399286A1 (en) 2020-12-24
EP4534148A2 (en) 2025-04-09
US20180339997A1 (en) 2018-11-29
US12410189B2 (en) 2025-09-09
IL267464B2 (en) 2023-05-01
IL298518B2 (en) 2025-05-01
EP3615541C0 (en) 2025-03-19
MX394540B (es) 2025-03-21
US20210094970A1 (en) 2021-04-01
JP6998969B2 (ja) 2022-02-10
AU2018259089B2 (en) 2022-05-12
AU2018259089A1 (en) 2019-07-04
JP2020517713A (ja) 2020-06-18
TWI826373B (zh) 2023-12-21
US11591345B2 (en) 2023-02-28
IL298518B1 (en) 2025-01-01
CA3048591A1 (en) 2018-11-01
AU2018259089A9 (en) 2019-10-10
WO2018197653A9 (en) 2019-09-19
CN110650963A (zh) 2020-01-03
US20230167128A1 (en) 2023-06-01
KR102342776B1 (ko) 2021-12-23
BR112019013292A2 (pt) 2019-12-10
EP4534148A3 (en) 2025-05-21
EP3615541A1 (en) 2020-03-04
PL3615541T3 (pl) 2025-06-23
TW201843160A (zh) 2018-12-16
ES3027566T3 (en) 2025-06-16
JP2021181446A (ja) 2021-11-25
IL317762A (en) 2025-02-01
US11028100B2 (en) 2021-06-08
IL298518A (en) 2023-01-01
EP3615541B1 (en) 2025-03-19
KR20190133724A (ko) 2019-12-03
MX2019012507A (es) 2019-12-19
IL267464A (en) 2019-08-29
IL267464B1 (en) 2023-01-01

Similar Documents

Publication Publication Date Title
US12410189B2 (en) Polymorphs and solid forms of (S)-2-2((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide, and methods of production
JP7042812B2 (ja) トリアゾロピリミジン化合物の結晶形態
TWI876835B (zh) B-raf激酶抑制劑的馬來酸鹽、其結晶形式及用途
TW202115093A (zh) Ｃｆｔｒ調節劑之結晶形式
JP6501773B2 (ja) 結晶形態のダサチニブの塩
TWI638818B (zh) ２－（４－（２－（１－異丙基－３－甲基－１ｈ－１，２，４－三唑－５－基）－５，６－二氫苯并［ｆ］咪唑并［１，２－ｄ］［１，４］氧氮呯－９－基）－１ｈ－吡唑－１－基）－２－甲基丙醯胺之多晶型、製造方法及醫藥用途
HK40020487B (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
HK40020487A (en) Polymorphs and solid forms of gdc-0077, and methods of production thereof
HK40124018A (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
BR112019013292B1 (pt) Polimorfos anidratos cristalinos, polimorfo triidrato cristalino, composições farmacêuticas, processo para preparar um polimorfo cristalino e uso de um polimorfo cristalino
HK1223101B (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof
HK40003818A (en) Polymorphs of gdc-0032, methods of production, and pharmaceutical uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020487

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant